In the era of precision medicine, multivalent and multispecific therapeutics present a
promising approach for targeted disease intervention. These therapeutics are designed to …

The emergence of the highly contagious Omicron variant of SARS-CoV-2 has inflicted
significant damage during the ongoing COVID-19 pandemic. This new variant's significant …

The continuous emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) variants with increased transmissibility and profound immune-escape capacity makes it …

Nanobodies are natural anti-SARS-CoV-2 drug candidates. Engineering multivalent
nanobodies is an effective way to improve the functional binding affinity of natural …

The global impact of zoonotic viral outbreaks underscores the pressing need for innovative
antiviral strategies, particularly against respiratory zoonotic RNA viruses. These viruses …

Viral nanoparticles (VNPs) are a new class of virus‐based formulations that can be used as
building blocks to implement a variety of functions of potential interest in biotechnology and …

Abstract SARS-CoV-2, a type of respiratory virus, has exerted a great impact on global
health and economy over the past three years. Antibody-based therapy was initially …

Abstract SARS-CoV-2 (COVID-19) pandemic has been an unpredicted burden on global
healthcare system by infecting over 700 million individuals, with approximately 6 million …

Almost all the neutralizing antibodies targeting the receptor-binding domain (RBD) of spike
(S) protein show weakened or lost efficacy against severe acute respiratory syndrome …

SARS‐CoV‐2 viruses are highly transmissible and immune evasive. It is critical to develop
broad‐spectrum prophylactic and therapeutic antibodies for potential future pandemics …